These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 8390845)

  • 41. Elevation of soluble interleukin-2 receptor in patients with non-small cell lung cancer treated with gefitinib.
    Kanazawa S; Yamaguchi K; Kinoshita Y; Komiyama Y; Muramatsu M; Nomura S
    J Cancer Res Clin Oncol; 2006 Nov; 132(11):719-25. PubMed ID: 16835747
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Macrophage-mediated immunostimulation modulates therapeutic efficacy of interleukin-2 based chemoimmunotherapy in advanced metastatic melanoma patients.
    Bernengo MG; Quaglino P; Cappello N; Lisa F; Osella-Abate S; Fierro MT
    Melanoma Res; 2000 Feb; 10(1):55-65. PubMed ID: 10711641
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinical value of soluble interleukin-2 receptor in infectious complications.
    Iwagaki H; Hizuta A; Iwadou H; Perdomo JA; Tanaka N; Orita K
    Acta Med Okayama; 1994 Aug; 48(4):225-6. PubMed ID: 7817778
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Phase I trial of intravenous infusion of ex-vivo-activated autologous blood-derived macrophages in patients with non-small-cell lung cancer: toxicity and immunomodulatory effects.
    Faradji A; Bohbot A; Schmitt-Goguel M; Roeslin N; Dumont S; Wiesel ML; Lallot C; Eber M; Bartholeyns J; Poindron P
    Cancer Immunol Immunother; 1991; 33(5):319-26. PubMed ID: 1651160
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Immunotherapy with low-dose subcutaneous interleukin-2 plus beta-interferon as a second-line therapy for metastatic colorectal carcinoma.
    Barni S; Lissoni P; Ardizzola A; Vigoré L; Vezzo R; Rescaldani R; Tancini G
    Tumori; 1993 Oct; 79(5):343-6. PubMed ID: 8116079
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Activation of the immune system of cancer patients by continuous i.v. recombinant IL-2 (rIL-2) therapy is dependent on dose and schedule of rIL-2.
    Gratama JW; Bruin RJ; Lamers CH; Oosterom R; Braakman E; Stoter G; Bolhuis RL
    Clin Exp Immunol; 1993 May; 92(2):185-93. PubMed ID: 8485906
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Neuroimmunotherapy of human cancer with interleukin-2 and the neurohormone melatonin: its efficacy in preventing hypotension.
    Lissoni P; Brivio F; Barni S; Tancini G; Cattaneo G; Archili C; Conti A; Maestroni GJ
    Anticancer Res; 1990; 10(6):1759-61. PubMed ID: 2285255
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Adoptive immunotherapy of human cancer: the cytokine cascade and monocyte activation following high-dose interleukin 2 bolus treatment.
    Boccoli G; Masciulli R; Ruggeri EM; Carlini P; Giannella G; Montesoro E; Mastroberardino G; Isacchi G; Testa U; Calabresi F
    Cancer Res; 1990 Sep; 50(18):5795-800. PubMed ID: 2118421
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Abrogation of the negative influence of opioids on IL-2 immunotherapy of renal cell cancer by melatonin.
    Lissoni P; Mandalà M; Brivio F
    Eur Urol; 2000 Jul; 38(1):115-8. PubMed ID: 10859453
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Elevated serum levels of neopterin and soluble interleukin-2 receptor in patients with ovarian cancer.
    Gadducci A; Ferdeghini M; Malagnino G; Prontera C; Fanucchi A; Annicchiarico C; Bianchi R; Fioretti P; Facchini V
    Gynecol Oncol; 1994 Mar; 52(3):386-91. PubMed ID: 8157196
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Low-dose interleukin-2 in combination with interferon-alpha effectively modulates biological response in vivo.
    Schneekloth C; Körfer A; Hadam M; Lopez Hänninen E; Menzel T; Schomburg A; Dallmann I; Kirchner H; Poliwoda H; Atzpodien J
    Acta Haematol; 1993; 89(1):13-21. PubMed ID: 7683166
    [TBL] [Abstract][Full Text] [Related]  

  • 52. IL-6 is a survival prognostic factor in renal cell carcinoma.
    Thiounn N; Pages F; Flam T; Tartour E; Mosseri V; Zerbib M; Beuzeboc P; Deneux L; Fridman WH; Debré B
    Immunol Lett; 1997 Jul; 58(2):121-4. PubMed ID: 9271323
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Which immunological parameters are clinically essential to monitor IL-2 cancer immunotherapy?
    Lissoni P; Brivio F; Viviani S; Fumagalli L
    J Biol Regul Homeost Agents; 1999; 13(2):110-4. PubMed ID: 10503734
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma.
    de Gast GC; Klümpen HJ; Vyth-Dreese FA; Kersten MJ; Verra NC; Sein J; Batchelor D; Nooijen WJ; Schornagel JH
    Clin Cancer Res; 2000 Apr; 6(4):1267-72. PubMed ID: 10778950
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Biologic and clinical effects of continuous infusion interleukin-2 in patients with non-small cell lung cancer.
    Ardizzoni A; Bonavia M; Viale M; Baldini E; Mereu C; Verna A; Ferrini S; Cinquegrana A; Molinari S; Mariani GL
    Cancer; 1994 Mar; 73(5):1353-60. PubMed ID: 8111701
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Correlation of interleukin-2 receptor and neopterin secretion in rheumatoid arthritis.
    Kullich W
    Clin Rheumatol; 1993 Sep; 12(3):387-91. PubMed ID: 8258242
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Dendritic cell immunotherapy combined with cytokine-induced killer cells promotes skewing toward Th2 cytokine profile in patients with metastatic non-small cell lung cancer.
    Zhao P; Bu X; Wei X; Sun W; Xie X; Li C; Guo Q; Zhu D; Wei X; Gao D
    Int Immunopharmacol; 2015 Apr; 25(2):450-6. PubMed ID: 25698555
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Combination immunotherapy for non-small cell lung cancer. Results with interleukin-2 and tumor necrosis factor-alpha.
    Yang SC; Owen-Schaub L; Mendiguren-Rodriguez A; Grimm EA; Hong WK; Roth JA
    J Thorac Cardiovasc Surg; 1990 Jan; 99(1):8-12; discussion 12-3. PubMed ID: 2152954
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Functional and immunophenotypic modifications induced by interleukin-2 did not predict response to therapy in patients with renal cell carcinoma.
    Favrot MC; Combaret V; Negrier S; Philip I; Thiesse P; Freydel C; Bijmann JT; Franks CR; Mercatello A; Philip T
    J Biol Response Mod; 1990 Apr; 9(2):167-77. PubMed ID: 1971303
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A direct comparison of immunological and clinical effects of interleukin 2 with and without interferon-alpha in humans.
    Schiller JH; Hank J; Storer B; Borchert AA; Moore KH; Albertini M; Bechhofer R; Wesley O; Brown RR; Bastin AM
    Cancer Res; 1993 Mar; 53(6):1286-92. PubMed ID: 8443808
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.